Bluejay Completes Enrollment in Pivotal Sepsis Test Study, Eyes FDA Submission
BJDX is trading near its 52-week low of $1.03 (14% above the low) on light trading volume (0.2× avg).
Summary
Bluejay Diagnostics completed enrollment in its SYMON-II pivotal study for the Symphony IL-6 sepsis test, hitting the 750-patient target ahead of schedule. Preliminary data shows a 17% 28-day mortality rate, providing a robust dataset for validation. The company plans to use results to support a 510(k) FDA submission, marking a key step toward commercialization. This follows a recent $8.5 million private placement that extended the cash runway, though the company still faces a going concern warning. The milestone de-risks the regulatory path for its lead product, but ultimate success hinges on positive study results and FDA clearance.
At the time of this announcement, BJDX was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $1.03 to $16.68. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.